Electroencephalography spectral edge frequency and suppression rate-guided sedation in patients with COVID-19: A randomized controlled trial

• DOI: 10.3389/fmed.2022.1013430
• Publication Date: 2022-11-04T04:50:44Z
• Authors: Eduardo Tobar; José I. Farías; Verónica Rojas; Antonello Penna; José I. Egaña; Daniela Ponce; Daniela Bravo; Felipe Maldonado; Abraham Gajardo; Rodrigo Gutiérrez
• Keywords: 2019-20 coronavirus outbreak

Sedation in coronavirus disease 2019 (COVID-19) patients has been identified as a major challenge. We aimed to investigate whether the use of multiparameter electroencephalogram (EEG) protocol guide sedation COVID-19 would increase 30-day mechanical ventilation-free days (VFD). conducted double-blind randomized clinical trial. included with severe pneumonia due who required ventilation (MV) and deep sedation. control (n = 25) or group 25). intervention was administered following standard institutional protocols together flow chart designed reduce propofol administration dose if EEG suppression rate over 2% spectral edge frequency 95 (SEF95) below 10 Hz. performed an intention-to-treat analysis evaluate our primary outcome (30-day VFD). There no difference VFD at day 30 (median: 11 [IQR 0-20] vs. 0 0-21] BIS group, p 0.87). Among secondary outcomes, we documented 17% reduction total adjusted during first 5 [median: 2.3 (IQR 1.9-2.8) mg/k/h 1.9(IQR 1.5-2.2) MP 0.005]. This accompanied by higher average value throughout treatment period. A guided multivariate EEG-derived parameters did not VFD. However, led administration.